Efficacy of an executive function intervention programme in MS: a placebo-controlled and pseudo-randomized trial

Area of Science:

• Neuroscience
• Rehabilitation Medicine
• Clinical Psychology

Background:

• Multiple sclerosis (MS) frequently causes executive deficits, impacting daily functioning.
• Cognitive rehabilitation is a potential strategy to address these deficits in MS patients.
• Understanding factors influencing treatment response is crucial for personalized care.

Purpose of the Study:

• To evaluate the efficacy of a cognitive intervention program for executive deficits in multiple sclerosis (MS) patients.
• To compare outcomes between a cognitive intervention group (CIG), a placebo group, and an untreated group.
• To explore the relationship between baseline brain atrophy and treatment effects.

Main Methods:

• A randomized controlled trial comparing a cognitive intervention group (n=11) with a placebo group (n=14) and an untreated group (n=15).
• Assessment of executive functioning and verbal learning using standardized outcome scores.
• Quantification of baseline brain atrophy using brain parenchymal fraction.

Main Results:

• The CIG demonstrated significant improvements in executive functioning and verbal learning compared to both control groups.
• The positive treatment effect on verbal learning was sustained at the 1-year follow-up.
• Baseline brain parenchymal fraction was associated with treatment effects in specific aspects of executive functioning.

Conclusions:

• Cognitive intervention programs show promise for improving executive deficits in multiple sclerosis.
• Verbal learning improvements can be long-lasting following cognitive rehabilitation.
• Brain atrophy at baseline may serve as a predictive biomarker for treatment outcomes in executive functioning for MS patients.